Clinical experience with Sandostatin LAR ( R) in patients with acromegaly

Author： Heijckmann C.A. Menheere P.P.C.A. Sels J.-P.J.E. Beuls E.A.M. Wolffenbuttel B.H.R.

Publisher： Elsevier

ISSN： 0300-2977

Source： The Netherlands Journal of Medicine, Vol.59, Iss.6, 2001-12, pp. : 286-291

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors

By Gregersen Tine Grøønbææk Henning Worsøøe Jonas Schlageter Vincent Laurberg Søøren Krogh Klaus

Scandinavian Journal of Gastroenterology, Vol. 46, Iss. 7-8, 2011-07 ,pp. : 895-902

Informa Healthcare

Access to resources Recommend Favorite

Regression of a Large Malignant Gastrinoma on Treatment with Sandostatin LAR®: A Case Report

Digestion, Vol. 77, Iss. 2, 2008-03 ,pp. : 92-95

Karger

Access to resources Recommend Favorite

Sandostatin^® LAR^® Leaders Meeting – European Neuroendocrine Tumour Network ENET

Digestion, Vol. 62, Iss. 1, 2000-07 ,pp. : 98-107

Karger

Access to resources Recommend Favorite

Spotlight on Octreotide Long-Acting Release (LAR) in Acromegaly

By McKeage Kate Cheer Susan Wagstaff Antona J.

Treatments in Endocrinology, Vol. 3, Iss. 3, 2004-01 ,pp. : 197-200

Adis International

Access to resources Recommend Favorite

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review

By Fleseriu Maria

Pituitary, Vol. 14, Iss. 2, 2011-06 ,pp. : 184-193

Springer Publishing Company

Access to resources Recommend Favorite